RESEARCH MONOGRAPH · KDC-MN-1309
Bupivacaine
Bupivacaine (Marcaine, Sensorcaine) is a long-acting amide local anesthetic introduced in 1965, the n-butyl analog of mepivacaine sharing the pipecoloxylidide scaffold. The longer alkyl chain confers higher lipid solubility, longer duration (4 to 8 hours), and greater protein binding. It is sold as a racemate. The major safety story is cardiotoxicity from inadvertent intravascular injection during regional anesthesia: the (R)-enantiomer binds cardiac sodium channels tightly and dissociates slowly, producing ventricular arrhythmias and refractory cardiovascular collapse that historically resisted standard ACLS. Intravenous lipid emulsion (Intralipid 20 percent) is the rescue therapy, supported by case series and animal data showing reduced collapse mortality. The cardiotoxicity drove development of the (S)-enantiomer levobupivacaine. Still widely used for spinal, epidural, peripheral nerve block, and obstetric epidural. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Amide local anesthetic (long-acting)
A long-acting butyl-substituted pipecoloxylidide racemic local anesthetic with high cardiotoxicity that motivated development of the (S)-enantiomer levobupivacaine.
Abstract
Bupivacaine (1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 2180-92-9; molecular formula C18H28N2O; molecular weight 288.43) is a long-acting amide local anesthetic synthesized by Bo af Ekenstam at AB Bofors in 1957 and introduced clinically in 1965 (Marcaine, Sensorcaine). The compound is the n-butyl analog of mepivacaine and shares the pipecoloxylidide scaffold; the longer alkyl chain confers higher lipid solubility, longer duration, and greater protein binding. Bupivacaine is sold as a racemate of (R)- and (S)-enantiomers; the cardiotoxicity that distinguishes bupivacaine from shorter-acting amides is enantioselectively driven by the (R)-enantiomer, which has higher affinity for cardiac sodium channels and longer dissociation kinetics. Mechanism is voltage-gated sodium channel block, state-dependent and slowly dissociating, the slow kinetics underlying both the prolonged neural block and the elevated arrhythmogenic risk relative to lidocaine. Onset for infiltration is 5 to 10 minutes; duration is 4 to 8 hours, longer with epinephrine adjunct. The principal historical safety concern is cardiac arrest from inadvertent intravascular injection during regional anesthesia: bupivacaine binds the cardiac sodium channel and dissociates slowly, producing ventricular arrhythmias and refractory cardiovascular collapse that proved historically resistant to standard ACLS algorithms. Intravenous lipid emulsion (Intralipid 20 percent) is the rescue therapy, supported by case series and animal data showing reduction in cardiovascular collapse mortality. Bupivacaine remains widely used for surgical regional anesthesia (spinal, epidural, peripheral nerve block) and obstetric epidural analgesia.
Mechanism of action
Slowly-dissociating voltage-gated sodium channel block. Cardiotoxicity primarily driven by (R)-enantiomer affinity for cardiac sodium channels.
Reported research dose ranges
Reported research dose ranges vary across the published literature.
References
- Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979.
- Clarkson CW, Hondeghem LM. Mechanism for bupivacaine depression of cardiac conduction. Anesthesiology 1985.
- Weinberg GL, et al. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole. Anesthesiology 1998.
Read the full monograph
Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.